軟組織移植片の世界市場 - 世界の産業規模、シェア、動向、機会、予測、2018年～2028年、タイプ別、用途別、エンドユーザー別、地域別、競合

世界の軟組織移植片市場は、2022年に48億米ドルと評価され、2028年までのCAGRは7.40%で、予測期間中に目覚ましい成長を遂げると予測されています。

軟組織移植片は、腱、靭帯、皮膚、その他の結合組織などのヒト軟部組織をドナーからレシピエントに移植する医療用移植片です。軟組織移植片は、レシピエントの体内の損傷または欠損した軟部組織を修復、置換、補強するための様々な医療処置に使用されます。軟組織移植片はヒトのドナーから供給されます。このドナーには、生存している個人と死亡した個人があります。生きているドナーは皮膚や血液成分などの組織を提供し、死亡したドナーは臓器・組織提供プログラムを通じて組織を提供することができます。ドナーの組織が回収されると、細胞やその他の細胞成分を除去するプロセスを経て、細胞外マトリックス（ECM）が残る。ECMは組織の構造的枠組みです。処理された組織は、その構造的完全性と機能性を維持するために保存されます。

特に整形外科やスポーツ医学の分野で外科手術の件数が増加していることが、軟組織移植片の需要を牽引しています。ACL再建術、半月板修復術、腱板修復術などの手術では、軟組織移植片が必要とされることが多いです。世界の高齢化により、筋骨格系の問題や怪我が増加しています。軟組織移植片はこのような問題に対処するために使用されるようになり、需要の増加につながりました。組織処理と保存技術の進歩により、軟組織移植片の品質と入手性が向上していました。このような技術の進歩により、軟組織移植片はヘルスケア提供者にとってより魅力的なものとなっていました。軟組織移植片は、再生医療におけるより広範な動向の一部と見なされていました。軟組織移植片は、自然治癒過程を促進する可能性があり、その使用への関心を高めていました。ドナー部位の罹患率の低下や回復時間の短縮により、自家移植よりも同種移植を好む患者もおり、市場の成長に寄与しています。

主な市場促進要因

技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の軟組織移植片市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別（羊膜移植片、軟骨、コラーゲン移植片、歯科用移植片、半月板移植片、腱移植片）
  • 用途別（歯科、整形外科、創傷治療）
  • エンドユーザー別（病院・クリニック、外来診療センター、その他）
  • 企業別（2022年）
• 市場マップ

第6章 アジア太平洋の軟組織移植片市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• アジア太平洋：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の軟組織移植片市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の軟組織移植片市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の軟組織移植片市場の展望

• 市場規模と予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの軟組織移植片市場の展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • タイプ別
  • 用途別
  • エンドユーザー別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 軟組織移植片の世界市場SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTLE分析

第16章 競合情勢

• CONMED Corporation
  • 事業概要
  • 企業スナップショット
  • 製品・サービス
  • 財務
  • 近年の発展
  • SWOT分析
• XTANT MEDICAL
  • 事業概要
  • 企業スナップショット
  • 製品・サービス
  • 財務
  • 近年の発展
  • SWOT分析
• ALONSOURCE GROUP
  • 事業概要
  • 企業スナップショット
  • 製品・サービス
  • 財務
  • 近年の発展
  • SWOT分析
• Becton & Dickinson Co.
  • 事業概要
  • 企業スナップショット
  • 製品・サービス
  • 財務
  • 近年の発展
  • SWOT分析
• Arthrex, Inc
  • 事業概要
  • 企業スナップショット
  • 製品・サービス
  • 財務
  • 近年の発展
  • SWOT分析
• Integra LifeSciences
  • 事業概要
  • 企業スナップショット
  • 製品・サービス
  • 財務
  • 近年の発展
  • SWOT分析
• Stryker Corporation
  • 事業概要
  • 企業スナップショット
  • 製品・サービス
  • 財務
  • 近年の発展
  • SWOT分析
• Institut Straumann AG
  • 事業概要
  • 企業スナップショット
  • 製品・サービス
  • 財務
  • 近年の発展
  • SWOT分析
• Organogenesis Inc
  • 事業概要
  • 企業スナップショット
  • 製品・サービス
  • 財務
  • 近年の発展
  • SWOT分析

第17章 戦略的提言

第18章 調査会社・免責事項

Global Soft Tissue Allograft Market has valued at USD 4.80 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.40% through 2028. Soft tissue allograft is a medical graft or transplant of human soft tissue, such as tendons, ligaments, skin, or other connective tissues, from a donor to a recipient. Soft tissue allografts are used in various medical procedures to repair, replace, or augment damaged or deficient soft tissues within the recipient's body. Soft tissue allografts are sourced from human donors. These donors can be living or deceased individuals. Living donors may donate tissues like skin or blood components, while deceased donors can provide tissues through organ and tissue donation programs. Once donor tissue is collected, it undergoes a process to remove cells and other cellular components, leaving behind the extracellular matrix (ECM). The ECM is the structural framework of tissue. The processed tissue is then preserved to maintain its structural integrity and functionality.

The rising number of surgical procedures, especially in orthopedic and sports medicine fields, was driving the demand for soft tissue allografts. Procedures like ACL reconstruction, meniscal repair, and rotator cuff repair often require these allografts. An aging global population was leading to an increase in musculoskeletal issues and injuries. Soft tissue allografts were being used to address these issues, leading to higher demand. Advances in tissue processing and preservation techniques were improving the quality and availability of soft tissue allografts. These technological advancements were making allografts more appealing to healthcare providers. Soft tissue allografts were seen as a part of the broader trend in regenerative medicine. They have the potential to enhance natural healing processes, driving interest in their use. Some patients preferred allografts over autografts due to reduced donor site morbidity and faster recovery times, contributing to the market's growth.

Key Market Drivers

Technological Advancements

Cryopreservation techniques have improved the long-term storage and viability of allograft tissues. This technology involves freezing tissues at extremely low temperatures to preserve their cellular integrity until they are needed for transplantation. Advanced sterilization methods, such as gamma irradiation and electron beam irradiation, have been developed to ensure the safety of allograft tissues while preserving their structural and functional properties. Decellularization processes have become more refined, allowing for the removal of cellular components from donor tissues while preserving the extracellular matrix (ECM). This ECM serves as a scaffold for tissue regeneration when implanted. Automated and computer-assisted quality control measures have been implemented to assess the safety and quality of allograft tissues. These measures help detect potential contaminants and ensure compliance with regulatory standards. Laboratories use more sophisticated biological testing methods to screen donor tissues for infectious agents and assess the compatibility of allografts with recipient tissues. Some soft tissue allografts incorporate live cells to enhance tissue regeneration. These cellular therapies may involve mesenchymal stem cells (MSCs) or other cell types to promote healing and tissue repair.

Growth factor technologies, such as platelet-rich plasma (PRP) and recombinant growth factors, are often combined with allografts to accelerate tissue healing and regeneration. Advancements in arthroscopy allow for minimally invasive procedures using smaller incisions. This reduces patient recovery time and minimizes tissue trauma when using soft tissue allografts in orthopedic applications. Some technologies enable the customization of allografts to match the specific needs of individual patients. This tailoring can improve the precision and success of transplantation. 3D printing and bioprinting technologies have enabled the creation of complex, patient-specific scaffolds that can be combined with soft tissue allografts to support tissue regeneration. Innovations in smart materials and coatings have led to the development of allografts with controlled release mechanisms for drugs, growth factors, or other bioactive substances, enhancing the graft's regenerative properties. Advanced imaging techniques, such as MRI and CT scans, provide detailed preoperative planning and intraoperative guidance for soft tissue allograft procedures. Barcode and RFID tracking systems help ensure the traceability of allograft tissues throughout the supply chain, from donor to recipient. This factor will help in the development of the Global Soft Tissue Allograft Market.

Increasing Surgical Procedures

Soft tissue allografts are frequently used in orthopedic surgeries, such as anterior cruciate ligament (ACL) reconstruction, meniscal repair, and rotator cuff repair. The rising incidence of musculoskeletal injuries and the aging population contribute to the increased demand for these procedures. Athletes often require surgical interventions to treat sports-related injuries, which can involve the use of soft tissue allografts. As sports and physical activities continue to gain popularity, the demand for sports medicine procedures and allografts rises. In plastic and reconstructive surgery, soft tissue allografts can be used for procedures like breast reconstruction, facial reconstruction, and tissue augmentation. An increasing number of individuals seek cosmetic and reconstructive surgeries, boosting the demand for these allografts. Soft tissue allografts are employed in dental and oral surgery for procedures such as gum grafting and ridge augmentation. The demand for dental implants and related surgeries has been on the rise. Surgical procedures to address chronic wounds, burns, and other injuries often require soft tissue allografts to support tissue healing and regeneration.

In ophthalmic surgery, amniotic membrane allografts are used for conditions like corneal defects and ocular surface reconstruction. As eye-related surgical procedures become more prevalent, so does the demand for these allografts. Soft tissue allografts can be used in various cosmetic procedures, such as lip augmentation and facial rejuvenation. The popularity of cosmetic surgery contributes to the demand for allografts in this field. While less common, soft tissue allografts are used in cardiovascular procedures, such as vascular grafts. The increasing prevalence of heart and vascular diseases drives the demand in this segment. In urology, soft tissue allografts can be used for procedures like urethral reconstruction. The demand for urological surgeries is influenced by factors like age-related urological conditions. Advances in surgical techniques have expanded the scope of procedures where soft tissue allografts can be used. Surgeons are increasingly incorporating allografts into their treatment plans. Minimally invasive surgical techniques, which often require smaller incisions and reduced tissue trauma, have become more prevalent. Soft tissue allografts are suitable for these less invasive approaches. This factor will pace up the demand of the Global Soft Tissue Allograft Market.

Increasing Aging Population

With age, individuals are more likely to develop musculoskeletal conditions such as osteoarthritis, ligament and tendon injuries, and degenerative joint diseases. These conditions frequently necessitate surgical procedures that involve the use of soft tissue allografts for repair and reconstruction. Soft tissue allografts are commonly used in orthopedic surgeries like joint replacements, ligament repairs, and cartilage restoration. The aging population's higher incidence of orthopedic problems leads to increased demand for these procedures and allografts. Older individuals continue to engage in physical activities, including sports and exercise, which can lead to sports-related injuries. Soft tissue allografts are employed in surgical procedures to treat these injuries, especially in middle-aged and older adults. As people age, their soft tissues, such as tendons and ligaments, tend to undergo degenerative changes, making them more susceptible to injuries. Allografts can be used to reinforce or repair these tissues.

Aging individuals often require dental and oral surgeries for issues like tooth loss, gum recession, and oral health complications. Soft tissue allografts may be used in these procedures to augment tissue and support dental implants. Older adults are more susceptible to chronic wounds, including diabetic ulcers and pressure sores, due to reduced skin elasticity and circulation. Soft tissue allografts can play a role in wound care and healing in this population. Cosmetic and reconstructive procedures that use soft tissue allografts are also in demand among older individuals who seek facial rejuvenation and correction of age-related aesthetic concerns. Aging is often accompanied by multiple medical comorbidities, such as cardiovascular disease and diabetes, which can lead to surgical interventions. Soft tissue allografts may be used in procedures related to these conditions. The aging population's interest in regenerative medicine and tissue engineering approaches to address age-related health issues has led to increased use of soft tissue allografts in regenerative therapies. Older adults often seek surgical interventions to maintain or improve their quality of life. Soft tissue allografts can support these interventions by enhancing tissue repair and function. This factor will accelerate the demand of the Global Soft Tissue Allograft Market.

Key Market Challenges

Tissue Shortages

The primary source of soft tissue allografts is human donors, both living and deceased. There is a finite supply of potential donors, and the availability of suitable tissues can be limited, especially in regions with low donor registration rates. Tissue banks and transplant organizations must adhere to stringent regulatory and safety requirements to ensure the quality and safety of allograft tissues. Meeting these requirements can be resource-intensive and time-consuming, which may affect the rate at which tissues become available for transplantation. Not all individuals are eligible to donate tissues due to medical or lifestyle factors. This further restricts the pool of potential donors. Comprehensive screening and testing processes are conducted to assess the suitability of donor tissues and ensure they are free from infectious diseases and other contaminants. These processes can result in the exclusion of some potential donors. Ensuring the quality of allograft tissues is paramount to patient safety. Tissues that do not meet quality standards are discarded, contributing to potential shortages. Tissue availability can vary by region, leading to disparities in access to allografts. Areas with fewer donor registrations may experience more pronounced shortages. Some procedures require tissue matching between donors and recipients to minimize the risk of rejection. Finding suitable matches can be challenging, especially for rare tissue types. The demand for soft tissue allografts has been on the rise, driven by an aging population and increasing surgical procedures. High demand can strain the available supply of donor tissues.

Supply Chain Vulnerabilities

The soft tissue allograft supply chain relies on the availability of suitable donors. Any disruptions in the donor pool, such as a decrease in donor registration rates or regulatory changes affecting donor eligibility, can affect the supply of allograft tissues. Stringent regulatory requirements and compliance standards must be met throughout the supply chain to ensure the safety and quality of allograft tissues. Non-compliance or regulatory changes can disrupt the supply chain. The screening and testing processes for potential donors are critical for safety but can introduce delays and vulnerabilities if issues arise, such as the need for additional testing or the exclusion of potential donors. Maintaining the integrity of allograft tissues during transportation and storage is essential. Temperature control, proper packaging, and logistics must be carefully managed to prevent tissue damage or contamination. Processing facilities must adhere to strict protocols to process and preserve allograft tissues. Failures in processing can result in the rejection of tissues or supply chain disruptions. Quality control measures must be consistently applied to assess the safety and suitability of allograft tissues. Any quality issues can lead to tissue rejection or recalls, disrupting the supply chain. Inventory management is critical to ensuring an adequate supply of allograft tissues to meet demand. Inaccurate forecasting or supply chain inefficiencies can result in shortages or overstocking. Distributing allograft tissues to healthcare providers in a timely manner, especially in remote or underserved areas, can be logistically challenging and may contribute to supply chain vulnerabilities.

Key Market Trends

Biologics and Regenerative Medicine

Soft tissue allografts are considered biological solutions that harness the natural healing potential of the body. They provide a scaffold or matrix for cells to populate and regenerate tissue, making them an integral part of regenerative medicine. Regenerative medicine approaches emphasize the body's ability to heal and regenerate tissues. Soft tissue allografts are used in these procedures to augment the regenerative process, facilitating faster and more effective tissue repair. Soft tissue allografts are often combined with stem cells, platelet-rich plasma (PRP), and growth factors to enhance tissue regeneration. These bioactive components stimulate cell proliferation and tissue healing. In orthopedics and sports medicine, biologics and regenerative techniques have gained popularity. Soft tissue allografts play a role in procedures like ACL reconstruction and rotator cuff repair, which are critical in sports-related injuries. Biologic and regenerative approaches are used in wound care, especially in the treatment of chronic wounds like diabetic ulcers and pressure sores. Soft tissue allografts can promote tissue regeneration and wound healing. Cosmetic and reconstructive surgeons increasingly use biologics and soft tissue allografts to improve the outcomes of procedures such as breast reconstruction and facial rejuvenation. Biologic and regenerative techniques are applied in dental and periodontal surgeries. Soft tissue allografts can support gum grafting and ridge augmentation procedures, promoting tissue regeneration. Some soft tissue allografts can be customized to match the specific needs of individual patients. This customization can enhance their regenerative potential and clinical effectiveness.

Segmental Insights

Type Insights

In 2022, the Global Soft Tissue Allograft Market largest share was held by Dental Allograft segment and is predicted to continue expanding over the coming years. There has been a growing demand for dental procedures, including dental implant placements, periodontal surgeries, and ridge augmentations. These procedures often involve the use of dental allografts to support tissue regeneration and bone grafting. Dental implants have become a popular choice for replacing missing teeth, and dental allografts are often used to enhance the success of these procedures. The rise in implant dentistry may have driven the demand for dental allografts. Manufacturers may have developed innovative dental allograft products that offer improved performance, ease of use, and better outcomes. These advancements could make dental allografts more attractive to dental professionals. Increased awareness of the importance of periodontal health and the benefits of periodontal surgeries may have led to a higher demand for dental allografts in periodontal procedures.

Application Insights

In 2022, the Global Soft Tissue Allograft Market largest share was held by Wound Care segment and is predicted to continue expanding over the coming years. The prevalence of chronic wounds, such as diabetic ulcers and pressure sores, has been rising due to factors like an aging population and the increasing incidence of diabetes. Soft tissue allografts can be used in the treatment of these wounds. Advancements in wound care techniques and products, including the use of soft tissue allografts, have led to improved patient outcomes. Healthcare providers may be increasingly turning to allografts for wound healing. Soft tissue allografts are often considered a part of the broader field of regenerative medicine. This perspective may have led to greater interest in their application in wound care for promoting tissue regeneration and faster healing. Unlike orthopaedic or sports medicine procedures that typically require surgery, wound care often involves non-surgical interventions. Soft tissue allografts can be used in less invasive wound healing approaches, making them accessible to a broader patient population.

End-User Insights

In 2022, the Global Soft Tissue Allograft Market largest share was held by Hospitals & Clinics segment in the forecast period and is predicted to continue expanding over the coming years. Hospitals and clinics typically handle a significant volume of patients, including those in need of orthopaedic, sports medicine, and other surgical procedures that may require soft tissue allografts. This high patient volume drives the demand for these allografts. Hospitals and clinics often have specialized departments or centres dedicated to orthopaedic and sports medicine. These departments are equipped to perform a wide range of procedures, including those that involve soft tissue allografts. Patients are more likely to seek specialized care in these settings. Surgeons in hospital and clinic settings tend to have specialized training and expertise in performing complex procedures, including soft tissue allograft transplantation. Patients often trust these healthcare institutions and their surgical teams for such treatments.

Regional Insights

The North America region dominates the Global Soft Tissue Allograft Market in 2022. North America, particularly the United States and Canada, boasts highly advanced healthcare infrastructure and facilities. This includes state-of-the-art hospitals, specialized orthopedic and sports medicine clinics, and a well-developed network of healthcare providers. This infrastructure facilitates the adoption of soft tissue allografts for various medical procedures. North America is a leader in medical technology and research. The region is home to many innovative medical device companies and biotechnology firms that have developed advanced soft tissue allograft products and techniques. These technological advancements have contributed to the market's growth and dominance. Sports injuries, especially in the United States, are quite common due to the popularity of sports and physical activities. Athletes often require soft tissue allografts for procedures like ACL reconstruction or meniscal repair. The prevalence of sports-related injuries has boosted the demand for these allografts.

Recent Developments

In July 2022, the quadricep tendon has been added to the AlloConnex range of tendons, ligaments, and fascia by AlloSource, one of the leading allograft providers in the United States. AlloSource develops cutting-edge cellular and tissue allografts to assist surgeons in healing their patients. Recently, it has become more common to repair ligaments using a quadricep tendon. AlloSource's AlloConnex quadricep tendon, which is offered with or without the bone block for different surgical approaches, is a reliable solution for cruciate ligament surgeries. A wide range of operations that surgeons carry out are supported by the AlloConnex tendon and ligament portfolio. In addition to the novel quadricep tendon, the AlloConnex portfolio of specialised allografts also includes the patellar ligaments, Achilles, anterior tibialis, gracilis, peroneus longus, posterior tibialis, and semitendinosus tendons. The tendon supply offered by AlloSource consists of single strand, double strand, and pre-shaped variants.

In September 2022, AbbVie announced that the Committee for Medicinal Products for Human Use (CMHP) of the European Medicines Agency (EMA) had adopted a favourable opinion recommending the approval of risankizumab (SKYRIZI, 600 mg IV induction and 360 mg subcutaneous [maintenance therapy]) for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response, lost response, or were intolerant to conventional or biologic therapy. Adults who are eligible for systemic medication and have moderate to severe plaque psoriasis should take SKYRIZI. Adults with active psoriatic arthritis who have not responded well to, or who have become intolerable to, one or more disease-modifying antirheumatic medications (DMARDs) may use SKYRIZI alone or in combination with methotrexate (MTX).

Key Market Players

• CONMED Corporation

• XTANT MEDICAL

• ALONSOURCE GROUP

• Becton & Dickinson Co.

• Arthrex, Inc

• Integra LifeSciences

• Stryker Corporation

• Institute Straumann AG

• Organogenesis Inc.

Report Scope:

In this report, the Global Soft Tissue Allograft Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Soft Tissue Allograft Market, By Type:

• Amniotic Allograft
• Cartilage
• Elastic Cartilage
• Fibro Cartilage
• Hyaline Cartilage
• Collagen Allograft
• Dental Allograft
• Connective Tissue Graft
• Free Gingival Graft
• Pedicle Graft
• Meniscus Allograft
• Tendon Allograft
• Achilles Tendon
• Patellar Tendon
• Tibialis

Soft Tissue Allograft Market, By Application:

• Dentistry
• Aesthetics
• Dental Sensitivity
• Orthopedic
• General Orthopedic
• Reconstruction
• Spine Injuries
• Sports Medicine
• Wound Care

Soft Tissue Allograft Market, By End-User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

Global Soft Tissue Allograft Market, By region:

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Soft Tissue Allograft Market.

Available Customizations:

• Global Soft Tissue Allograft Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Soft Tissue Allograft Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Amniotic Allograft, Cartilage, Collagen Allograft, Dental Allograft, Meniscus Allograft, Tendon Allograft)
  • 5.2.2. By Application (Dentistry, Orthopedic, Wound Care)
  • 5.2.3. By End-User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.4. By Company (2022)
• 5.3. Market Map

6. Asia Pacific Soft Tissue Allograft Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Soft Tissue Allograft Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. India Soft Tissue Allograft Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Soft Tissue Allograft Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Soft Tissue Allograft Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Application
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Soft Tissue Allograft Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Application
      • 6.3.5.2.3. By End User

7. Europe Soft Tissue Allograft Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Soft Tissue Allograft Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Soft Tissue Allograft Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Soft Tissue Allograft Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Soft Tissue Allograft Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Soft Tissue Allograft Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. North America Soft Tissue Allograft Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Soft Tissue Allograft Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Soft Tissue Allograft Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Soft Tissue Allograft Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User

9. South America Soft Tissue Allograft Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Soft Tissue Allograft Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Soft Tissue Allograft Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Soft Tissue Allograft Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Soft Tissue Allograft Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Soft Tissue Allograft Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Soft Tissue Allograft Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Soft Tissue Allograft Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Soft Tissue Allograft Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. CONMED Corporation
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. XTANT MEDICAL
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. ALONSOURCE GROUP
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. Becton & Dickinson Co.
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. Arthrex, Inc
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. Integra LifeSciences
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Stryker Corporation
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. Institut Straumann AG
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Organogenesis Inc
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer